Exhibit 99.2

MERCK & CO., INC.    

CONSOLIDATED STATEMENT OF INCOME - GAAP    

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)    

(UNAUDITED)    

Table 1a    

* 100% or greater                                                        

Sum of quarterly amounts may not equal year-to-date amounts due to rounding.                                                        

MERCK & CO., INC.

FIRST QUARTER 2021 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)

Table 2b

The table below reflects a reconciliation of GAAP to non-GAAP financial information on a continuing operations basis.  As Organon results are reflected within discontinued operations, they are excluded from the financial information provided below.

Only the line items that are affected by non-GAAP adjustments are shown.

Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.

⁽¹⁾ Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets.  Amounts included in other (income) expense, net, primarily reflect royalty income, partially offset by an increase in the estimated fair value measurement of liabilities for contingent consideration related to the termination of the Sanofi-Pasteur MSD joint venture.

⁽²⁾ Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.

⁽³⁾ Represents a charge for the discontinuation of COVID-19 development programs.

⁽⁴⁾ Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Certain other items also includes a $208 million net tax benefit related to the settlement of certain federal income tax matters.

MERCK & CO., INC.

FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS

FIRST QUARTER 2022

(AMOUNTS IN MILLIONS)

(UNAUDITED)

Table 3a

* 200% or greater  

Sum of U.S. plus international may not equal global due to rounding.  

⁽¹⁾ Only select products are shown.  

⁽²⁾ Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.

⁽³⁾ Alliance Revenue represents royalties and a milestone payment.

⁽⁴⁾ Total Vaccines sales were $2,481 million in the first quarter of 2022 and $1,809 million in the first quarter of 2021.

⁽⁵⁾ Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.

⁽⁶⁾ Net product sales in Merck's marketing territories.

⁽⁷⁾ Total Diabetes sales were $1,305 million in the first quarter of 2022 and $1,363 million in the first quarter of 2021.

⁽⁸⁾ Includes Pharmaceutical products not individually shown above.

⁽⁹⁾ Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. Other Revenues in the first quarter of 2021 include $50 million related to the receipt of a milestone payment for an out-licensed product.

MERCK & CO., INC.  

PHARMACEUTICAL GEOGRAPHIC SALES - CONTINUING OPERATIONS  

(AMOUNTS IN MILLIONS)  

(UNAUDITED)  

Table 3b  

Sum of quarterly amounts may not equal year-to-date amounts due to rounding.    

⁽¹⁾ Europe represents all European Union countries, the European Union accession markets and the United Kingdom.    

MERCK & CO., INC.  

OTHER (INCOME) EXPENSE, NET - GAAP  

(AMOUNTS IN MILLIONS)  

(UNAUDITED)  

Table 4 

OTHER (INCOME) EXPENSE, NET        

⁽¹⁾ Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.  Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag.